RxDoctor Payments Data

Marc Dunn, MD

Pulmonary Disease · Troy, MINPI 1427002484

Payments from drug & device makers

$15,802in general payments, 2019–2025

Across 882 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$3K
  • Boehringer Ingelheim$2K
  • Mylan Specialty L.p.$915
  • Regeneron Healthcare Solutions, Inc.$790
  • Grifols USA, LLC$681
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$15,64799%
  • Education$1551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,802 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$184,581
Medicare patients
571
Services billed
2,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate23$305,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter239$232,846
Breo ElliptaFluticasone/Vilanterol141$89,439
Spiriva RespimatTiotropium Bromide109$86,254
Pirfenidone49$75,367
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$48,135
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$46,956
Fluticasone-SalmeterolFluticasone Propion/Salmeterol247$46,635
Stiolto RespimatTiotropium Br/Olodaterol Hcl56$36,620
SymbicortBudesonide/Formoterol Fumarate82$28,779
Incruse ElliptaUmeclidinium Bromide40$23,608
DuleraMometasone/Formoterol49$20,960
Albuterol Sulfate HfaAlbuterol Sulfate475$19,486
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate66$19,447
EliquisApixaban17$18,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$2,271$428,518188 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$2,819$404,642517 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$2,879$81,476154 claims
MerckDulera$59$20,96049 claims
PfizerEliquis$22$18,52117 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$156$8,82732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →